Allogene Therapeutics, Inc. (ALLO)
| Market Cap | 494.05M+5.9% |
| Revenue (ttm) | 4.64M |
| Net Income | -165.49M |
| EPS | -0.66 |
| Shares Out | 345.49M |
| PE Ratio | n/a |
| Forward PE | -2.19 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,888,391 |
| Open | 1.45 |
| Previous Close | 1.46 |
| Day's Range | 1.42 - 1.47 |
| 52-Week Range | 1.04 - 4.46 |
| Beta | 0.56 |
| Analysts | none |
| Price Target | 9.00(+529.37%) |
| Earnings Date | Nov 5, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About ALLO
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$ALLO stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in ALLO holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ALLO's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ALLO Estimated quarterly lobbying spending
Source: U.S. Senate LDA
ALLO Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Payroll | $14.48M | 35.30% |
| Facilities & IT-related spend | $7.29M | 17.76% |
| Cema-cel | $6.95M | 16.95% |
| Supporting external spend | $5.25M | 12.81% |
| Collaboration revenue - related party | $4.64M | 11.31% |
| All other development costs | $2.41M | 5.87% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New ALLO patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ALLO from public contracts
Source: USAspending.gov
ALLO Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ALLO’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score